Breaking News

OncoImmune’s IND Gains FDA Clearance

WuXi Biologics to provide CMC development and GMP manufacturing of the drug substance and drug product for next-gen anti-CTLA-4 antibody

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OncoImmune has received FDA clearance for its Investigational New Drug (IND) for ONC-392, a novel, next generation anti-CTLA-4 antibody. The company has partnered with WuXi Biologics to provide comprehensive services for the ONC-392 program, including CMC development and GMP manufacturing of the drug substance and drug product.   “It has been our great pleasure working with WuXi Biologics on our ONC-392 program. The clearance of ONC-392 IND by the FDA is an important milestone for OncoIm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters